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BACKGROUND: To assess differences in platelet inhibition during ticagrelor monotherapy (TIC) or dual therapy with ticagrelor 
and aspirin (TIC+ASP) in patients after percutaneous coronary intervention using a comprehensive panel of functional tests.
METHODS AND RESULTS: In a single-center parallel group, open label, randomized controlled trial, 110 participants were ran-
domized to receive either TIC (n=55) or TIC+ASP (n=55) for 4 weeks. The primary outcome was the platelet aggregation re-
sponse with 10 μmol/L thrombin receptor activation peptide-6 (TRAP-6). The secondary outcomes were platelet aggregation 
responses and binding of surface activation markers with a panel of other activators. The mean percentage aggregation for 
10 μmol/L TRAP-6 was similar for the TIC and TIC+ASP groups (mean difference+4.29; 95% CI, −0.87 to +9.46). Aggregation 
was higher in the TIC group compared with the TIC+ASP group with 1 μg/mL (+6.47; +2.04 to +10.90) and 0.5 μg/mL (+14.00; 
+7.63 to +20.39) collagen related peptide. Aggregation responses with 5 μmol/L TRAP-6, 5 μmol/L or 2.5 μmol/L thrombox-
ane A2 receptor agonist and surface activation marker binding with 5 μmol/L TRAP-6 or 0.5 μg/mL collagen related peptide 
were the same between the treatment groups.
CONCLUSIONS: Patients with PCI show similar levels of inhibition of most platelet activation pathways with TIC compared with 
dual therapy with TIC + ASP. However, the greater aggregation response with collagen related peptide during TIC indicates 
incomplete inhibition of glycoprotein VI (collagen) receptor-mediated platelet activation. This difference in pharmacodynamic 
response to anti-platelet medication may contribute to the lower bleeding rates observed with TIC compared with dual anti-
platelet therapy in recent clinical trials.
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Dual anti-platelet therapy (DAPT) with aspirin and a P2Y12 antagonist to additionally supress the ADP platelet activation pathway reduces the composite 
risk of myocardial infarction and cardiovascular death 
after percutaneous coronary intervention (PCI) when 
compared with aspirin monotherapy.1,2 Consequently, 
DAPT is the current standard anti-thrombotic regime.3,4 
Potent P2Y12 antagonists improve ischaemic protection 
when compared with clopidogrel, because they enable 
more consistent suppression of ADP-mediated plate-
let activation.5–7 However, the greater anti-thrombotic 
effect of potent P2Y12 antagonists is accompanied by 
increased bleeding.8
It has long been recognized that the ADP platelet 
activation pathway utilizes signalling mediators and 
effectors that are partially shared with the throm-
boxane A2 (TxA2) activation pathway, the target of 
inhibition by aspirin.9–11 In view of this potential re-
dundancy, monotherapy with a potent P2Y12 antag-
onist has been proposed as an alternative to DAPT, 
maintaining anti-thrombotic effect whilst avoiding 
bleeding associated with aspirin.12,13 In healthy vol-
unteers, potent P2Y12 antagonists diminish both 
ADP and TxA2-mediated platelet aggregation, sug-
gesting that additional aspirin is unnecessary for 
full platelet inhibition.10,14 However, in other studies 
a P2Y12 antagonist had minimal impact on the pro-
duction of the TxA2 metabolite, thromboxane B2, 
suggesting that the TxA2 pathway is incompletely 
inhibited.15
Despite the lack of conclusive data from healthy 
control studies, potent P2Y12 antagonist monotherapy 
has been compared to DAPT in several large random-
ized controlled trials in patients who had undergone 
PCI.16–18 Patients who were switched from DAPT 
to P2Y12 antagonist monotherapy, between 1 and 
3 months after PCI, had non-inferior composite rates 
of all-cause death or ischaemic events compared with 
patients remaining on DAPT, suggesting equivalent 
antithrombotic effect.17–19 Importantly, bleeding in pa-
tients switched to P2Y12 antagonist monotherapy was 
either lower17,19 or non-inferior18 when compared with 
patients remaining on DAPT.
Translation of the results from these trials into 
clinical practice remains unclear, primarily because 
the specific nature of the study designs and subject 
selection limits generalization of the results to all pa-
tients.20 In particular, the possible implementation 
of P2Y12 antagonist monotherapy to specific patient 
subgroups is currently hampered by the lack of a 
mechanistic understanding of the differences be-
tween the P2Y12 antagonist monotherapy and DAPT 
groups observed in the trials.16 In order to quantify 
differences in the pharmacodynamic effect of P2Y12 
antagonist monotherapy compared to DAPT, we 
randomized patients with PCI to receive either TIC 
or DAPT with ticagrelor and aspirin (TIC + ASP) and 
performed a comprehensive panel of platelet func-
tional tests on blood samples.
CLINICAL PERSPECTIVE
What Is New?
• In acute coronary syndrome treatment a deli-
cate balance between ischaemic protection 
and bleeding exists, hence studies comparing 
dual anti-platelet treatment with potent ADP re-
ceptor antagonist monotherapy - TEMPLATE 
(Ticagrelor Monotherapy and Platelet Reactivity) 
is the first dedicated study to assess the phar-
macodynamic effects of ticagrelor monother-
apy against aspirin and ticagrelor combination 
therapy in patients who have previously under-
gone percutaneous coronary intervention.
• Ticagrelor monotherapy provides similar plate-
let aggregation responses to agonists of the 
thrombin and thromboxane A2 receptor com-
pared with dual therapy but the aggregation 
response to an agonist specific to the platelet 
glycoprotein VI receptor (essential for normal 
haemostasis) was higher in the ticagrelor mono-
therapy group.
What Are the Clinical Implications?
• Considered alongside clinical outcome data, 
our findings support comprehensive platelet 
inhibition with dual anti-platelet therapy, early 
after percutaneous coronary intervention, when 
thrombotic risk is highest but suggest a poten-
tial advantage for subsequent cessation of as-
pirin to diminish bleeding by reducing platelet 
inhibition and specifically minimization of gas-
trointestinal tract bleeding for which aspirin is a 
contributory factor.
Nonstandard Abbreviations and Acronyms
AA arachidonic acid
CD62P platelet surface P-selectin
CRP collagen related peptide
DAPT dual antiplatelet therapy
GPVI receptor platelet glycoprotein VI receptor
PAC-1 activated GP IIb/IIIa
TIC ticagrelor monotherapy
TIC+ASP ticagrelor and aspirin dual 
therapy
TRAP-6 thrombin receptor activation 
peptide-6
TxA2 thromboxane A2
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METHODS
TEMPLATE Trial Design and Interventions
The TEMPLATE (Ticagrelor Monotherapy and Platelet 
Reactivity) study was a single-center, open-label, 
parallel group RCT (ISRCTN84335288). The study 
was approved by a UK Research Ethics Committee 
(14/SC/1309) and was authorized by the Medicines 
and Healthcare Regulatory Agency (EUDRACT No 
2013-002734-20). The study protocol has been re-
ported previously.21 The data generated from the 
trial are available from the corresponding author on 
request. The request must include a specification 
of the data requested and justification for that re-
quest (i.e. a statement of purpose for which the data 
are required). The data may not be released unless 
all Bristol Trials Centre and Sponsor requirements are 
fulfilled (e.g. protocol, sample size calculation, valid 
National Research Ethics Service Committee  and 
Health Research Authority approval if appropriate, 
a collaborative arrangement in place between the 
Sponsor and the external body).
Patients under the care of the Bristol Heart 
Institute, Bristol, UK were eligible for inclusion if they 
were adults aged >18 years receiving DAPT with as-
pirin and any P2Y12 antagonist after PCI for acute 
coronary syndrome (ACS) and for which there was a 
clinical intention to transfer to aspirin monotherapy. 
Patients were ineligible if there was a contra-indica-
tion to ticagrelor, if prior treatment with DAPT had 
been interrupted because of bleeding, if they were 
pregnant or breast feeding or if the patient was (or 
was a partner of) a woman with child-bearing poten-
tial unwilling to use contraception. Twelve months 
after the index PCI, when DAPT would normally 
be switched to aspirin monotherapy, consenting 
patients were randomized using a internet-based 
computer system ensuring allocation concealment. 
No blinding was used. Patients were allocated in a 
1:1 ratio to receive either TIC (TIC group; ticagrelor 
180  mg then 90  mg twice per day), or DAPT with 
ticagrelor and aspirin (TIC+ASP group; ticagre-
lor 180 mg then 90 mg twice per day plus aspirin 
75 mg once per day), for a total of 4 weeks. The tica-
grelor doses in the treatment arms were selected to 
reproduce current standard DAPT given for the first 
12  months after PCI. Participants in both groups 
were then switched to monotherapy with aspirin 
75  mg once per day for 4  weeks and returned to 
standard care. Blood samples were obtained during 
initial DAPT (blood sample 1), 4 weeks after alloca-
tion to the TIC or TIC+ASP groups (blood sample 2) 
and 4 weeks after transfer to aspirin monotherapy 
(blood sample 3; Figure  1). Safety outcomes were 
collected for the duration of the study or until partic-
ipant withdrawal.
Analysis of Blood Samples
Functional responses of platelet rich plasma obtained 
from venous blood samples were analyzed by light 
transmission aggregation using a PAP-8E plate-
let aggregometer (BioData, Horsham, PA, USA).21 
The platelets were stimulated with 10  μmol/L and 
5  μmol/L thrombin receptor activation peptide-6 
(TRAP-6), 1 μg/mL and 0.5 μg/mL collagen related 
peptide (CRP), 2.5 μmol/L and 5 μmol/L thromboxane 
A2 (TxA2) receptor agonist (U46619), 1  mmol/L ara-
chidonic acid (AA) or 10 μmol/L ADP. Reagents were 
obtained from Hart biologicals (Hartlepool, UK) ex-
cept for CRP (University of Cambridge, UK). Results 
were recorded as the maximum amplitude of aggre-
gation, expressed as a percentage of the difference in 
light transmission between platelet rich plasma and a 
plasma control.
Platelet surface activation markers were measured 
in unstimulated platelet rich plasma and in platelet 
rich plasma after stimulation with 1 μg/mL CRP or 
5 μmol/L TRAP-6 by incubated the samples with PE-
conjugated anti-CD62P (Becton Dickinson, Oxford, 
UK) and FITC-conjugated PAC-1 antibodies (Becton 
Dickinson) for 10 minutes at room temperature and 
then fixing in 1% paraformaldehyde. Antibody bind-
ing was measured on a BD FACSCanto TM II (BD 
Biosciences) and reported as the median fluores-
cence intensity (MFI) of antibody binding in unstim-
ulated platelets and the increase in MFI (ΔMFI) of 
antibody binding after stimulation.
Figure 1. Trial design.
DAPT indicates dual antiplatelet therapy; and PCI, percutaneous 
coronary intervention
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Outcomes
The primary outcome was the maximum amplitude of 
platelet aggregation after stimulation with 10 μmol/L 
TRAP-6. Secondary outcomes were the maximum 
amplitude of aggregation with the remaining activators 
and the binding of platelet surface activation markers. 
Outcomes were compared in blood sample 2, taken at 
the end of the intervention period.
Statistical Analysis
The sample size of 110 participants was chosen to pro-
vide a 95% CI of ±0.35 SD for the mean difference in 
10 μmol/L TRAP-6 between groups, assuming corre-
lation between pre- and post-treatment platelet func-
tion results of 0.5, with no crossover, and allowing for 
10% drop-out.
Participants were analyzed on an intention-to-treat 
basis and analyses were carried out according to a 
prespecified statistical analysis plan. To minimize the 
type 1 error rate, it was agreed a priori that the dif-
ference in the aggregation response with 10 μmol/L 
TRAP-6 (primary outcome) and in the aggregation 
responses with 1  μg/mL CRP, 1  mmol/L AA and 
10 μmol/L ADP would be quantified. Differences in 
aggregation responses for the remaining agonists 
were quantified posthoc. The binding of platelet sur-
face activation markers was described, but differ-
ences were not quantified.
Differences between the treatment groups were as-
sessed using longitudinal mixed effects multiple linear 
regression models that included data from all blood 
samples, with patients fitted as random intercepts 
and sample number as random slopes (depending 
on model fit, with unstructured covariance matrices). 
Treatment group, sample number and their interaction 
were included as fixed effects. Models were compared 
using the likelihood ratio test. Differences between the 
treatment groups were expressed as the difference in 
mean percentage of the maximum amplitude of aggre-
gation in blood sample 2, representing the model-ad-
justed absolute difference between the responses 
in the TIC+ASP group as the reference. All P values 
are 2-sided. Analyses were conducted using Stata 




Between December 2015 and July 2017, all 2967 pa-
tients listed for PCI at the study center underwent 
pre-screening to identify patients who could immedi-
ately be excluded because they did not meet the eligi-
bility criteria. The remaining 1186 patients underwent 
full screening for eligibility and were invited to join the 
study. Within this group, 182 patients were confirmed 
as eligible and expressed interest in participation. 
A total of 115 patients were approached, 112 gave 
consent and 110 were randomized (55 to TIC and 55 
to TIC+ASP; Figure 2). All participants provided the 
first blood sample at recruitment. Seven participants 
withdrew during the intervention period (first period 
of 4 weeks) and 1 withdrew after the trial intervention 
period (second period of 4 weeks). The reasons for 
withdrawal were participant request for an unspeci-
fied reason (3); participant unable to comply with 
study visits (2); primary care physician request to 
withdraw (1) and death of participant (1). One further 
participant was withdrawn because he was found to 
be ineligible from medical records that became avail-
able only after randomization.
Participant Characteristics
The clinical characteristics of the participants in the 2 
groups were similar (Table 1). Overall, 88 participants 
were male and mean age was 67 years. The median 
time from PCI to randomization was 366 days (IQR 360, 
374). All participants had received DAPT continuously 
since PCI, comprising aspirin and either ticagrelor 
Figure 2. Screening, eligibility, randomization and blood 
sampling.
ASP indicates aspirin; and TIC, ticagrelor monotherapy.
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(44%), clopidogrel (35%) or prasugrel (21%) according 
to standard institutional treatment protocols.
Platelet Function 4 Weeks After Allocation 
to Treatment Group (Sample 2)
The difference in mean percentage platelet aggrega-
tion with 10 μmol/L TRAP-6 (primary outcome) was 
similar in the 2 groups (aggregation with TIC minus 
TIC+ASP=+4.29; 95% CI, −0.87 to +9.46; P=0.103; 
Figures 3A and 4 and Table S1). Considering the sec-
ondary outcomes, aggregation was higher in the TIC 
group compared with the TIC+ASP group with 1 μg/
mL CRP (difference+6.47 (+2.04 to +10.90); P=0.004) 
and with 0.5 μg/mL CRP (difference +14.00 (+7.63 to 
+20.39); P < 0.001), indicating less platelet inhibition in 
Table. Characteristics of the Trial Population
TIC+ASP (n=55) TIC alone (n=55)
n % n %
Clinical characteristics
Age, y
Mean (SD) 67.3 (10.3) … 66.1 (11.8) …
Sex
Female 11/55 20 11/55 20
Male 44/55 80 44/55 80
Body mass index (kg/m2)
Mean (SD) 27.6 (3.8) … 27.0 (4.9) …
Smoking
Active smoker 6/55 11 7/55 13
Ex-smoker of more than 1 mo 29/55 53 27/55 49
Never smoked 20/55 36 21/55 38
Family history of heart disease 29/55 53 21/55 38
Hypertension requiring treatment 26/55 47 31/55 56
Hypercholesterolaemia 30/55 55 31/55 56
Diabetes mellitus
Insulin 3/55 5 4/55 7
Oral hypoglycaemic or diet 6/55 11 4/55 7
None 46/55 84 47/55 85
Congestive heart failure 4/55 7 1/55 2
Cerebrovascular disease 3/55 5 3/55 5
Chronic pulmonary disease 6/55 11 7/55 13
Peripheral vascular disease 2/55 4 1/55 2
Previous PCI* 12/55 22 15/55 27
Previous cardiac surgery 5/55 9 4/55 7
Previous myocardial infarction* 27/55 49 30/55 55
Left ventricular function
Good (>50%) 36/53 68 38/53 72
Moderate (30%-50%) 17/53 32 14/53 26
Poor (<30%) 0/53 0 1/53 2
Coronary artery disease
Single vessel 26/55 47 28/55 51
Double vessel 21/55 38 14/55 25
Triple vessel 8/55 15 13/55 24
Anti-platelet medication before randomization
Aspirin 55/55 100 55/55 100
Clopidogrel 19/55 35 20/55 36
Prasugrel 13/55 24 10/55 18
Ticagrelor 23/55 42 25/55 45
*Refers to percutaneous coronary intervention (PCI) of myocardial infarction prior to the index PCI considered in this study.
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the TIC group. There was no difference between the 
groups in platelet aggregation with 5 μmol/L TRAP-6, 
2.5 μmol/L U46619 or with 5 μmol/L U46619.
As expected, platelet aggregation was markedly 
higher in the TIC group compared with the TIC+ASP 
group with 1  mmol/L AA (difference +11.68 (+8.55 
to +15.95); P < 0.001). (Figures 3B and 4) which is a 
sensitive marker of platelet inhibition with aspirin. 
Aggregation was similar between the treatment groups 
with 10 μmol/L ADP (difference +1.15 (−4.89 to +7.19); 
P=0.709; Figures  3B and 4) and confirmed full sup-
pression of ADP-mediated platelet in both groups.
Participants in both groups had similarly low lev-
els of binding of the activation markers PAC 1 and 
anti-CD62P in unstimulated platelets. Although after 
stimulation with 5 μmol/L TRAP-6 or 1 μg/mL CRP, 
binding of both PAC 1 and anti-CD62P increased 
markedly, the extent of activation marker binding was 
similar in the 2 groups (Figure 5 and Table S2).
Platelet Function at Baseline and After 
Transfer to Aspirin Alone (Samples  
1 and 3)
No differences in aggregation or surface activation 
marker binding were found in blood samples 1 and 3 
(Figure 3, Figures S1 and S2, Tables S1–S2), consist-
ent with patients in both groups receiving the same 
classes of anti-platelet drugs at the time of these blood 
samples.
Adverse Outcomes
A total of 258 adverse events occurred during the 
entire trial period (Table S3), of which 188 occurred 
during the 4-week trial intervention period (98 events 
in 39 patients in the TIC group and 90 events in 37 
patients in the TIC+ASP group; Table S4). There were 
53 bleeding events during the 4-week intervention pe-
riod: 20 in the TIC group and 33 in the TIC+ASP group. 
Bleeding was predominantly subcutaneous or dermal 
in both groups and was mild (all bleeding events were 
Figure 3. Platelet light transmission aggregation 
responses.
Data represent the maximum amplitude of aggregation 
responses (medians and interquartile ranges) at visit 1 (all 
patients receiving DAPT), visit 2 (4 weeks after allocation to either 
TIC or TIC+ASP groups) and visit 3 (all patients receiving aspirin 
alone). P values are 2-tailed. A, Responses to thrombin receptor 
activation peptide 6 (TRAP-6), collagen related peptide (CRP) 
and thromboxane A2 receptor agonist (U46619). B, Responses to 
adenosine diphosphate (ADP) and arachidonic acid (AA).
Figure 4. Mean treatment differences in platelet 
aggregation responses in blood sample 2.
The whiskers indicate the 95% CIs of the mean treatment 
difference estimates. Estimates less than zero indicate that the 
aggregation responses in TIC+ASP group were greater than in TIC 
group. *represents posthoc comparisons of measures. P values 
are 2-tailed. AA indicates arachidonic acid; ADP, adenosine 
diphosphate; CRP, collagen related peptide; TRAP-6, thrombin 
receptor activation peptide 6; and U46619, thromboxane A2 
receptor agonist.
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Bleeding Academic Research Consortium Type 1).22 
One major adverse cardiac (fatal acute coronary syn-
drome) event occurred during the 4-week trial inter-
vention period in the TIC+ASP group.
DISCUSSION
The TEMPLATE study is the first randomized con-
trolled trial performed to assess differences between 
the pharmacodynamic effects of TIC and DAPT with 
TIC + ASP in patients who have previously under-
gone PCI. The study was performed in order to pro-
vide mechanistic insight into the extent of platelet 
inhibition with TIC. The panel of tests included func-
tional evaluation of the major platelet receptors for 
thrombin and collagen which are essential for normal 
haemostasis and initiate pathological thrombus for-
mation in acute coronary syndrome.23–25 We found 
the pharmacodynamic effect of TIC to be similar to 
previous studies with groups of patients with acute 
coronary syndrome.26,27 However our study also 
showed the primary outcome of platelet aggrega-
tion with 10  μmol/L TRAP-6 was the same in pa-
tients receiving TIC compared with patients receiving 
DAPT. However, platelet aggregation with 1 μg/mL or 
0.5 μg/mL CRP was higher in patients receiving TIC, 
indicating less complete platelet inhibition.
After 4 weeks of the allocated treatment, patients 
in both the TIC and TIC+ASP groups had reduced 
aggregation with 10  μmol/L ADP that was simi-
lar between groups, confirming that ticagrelor had 
fully suppressed the ADP-mediated activation path-
way in both groups. Conversely aggregation with 
1 mmol/L AA was markedly reduced in the TIC+ASP 
group compared with the TIC group, indicating the 
presence of aspirin, which potently inhibits the ag-
gregation response to AA by blocking synthesis of 
TxA2.
28,29 Having confirmed strong blockade of the 
ADP and TxA2 activation pathways by TIC and ASP 
respectively, we observed that platelet aggregation 
responses to TRAP-6 (protease activated (thrombin) 
receptor-1 agonist) and U46619 (TxA2 receptor ag-
onist) were similar between the treatment groups. 
This finding replicates data from previous studies 
using platelets from healthy volunteers incubated 
ex vivo with prasugrel active metabolite or with ti-
cagrelor10,14,15 or from healthy volunteers receiving 
prasugrel,30 and suggests that strong P2Y12 blockers 
duplicate the inhibitory effect of aspirin on the throm-
bin and TxA2 receptor activation pathways.
By contrast, we found that the aggregation re-
sponses to CRP, which is a specific agonist of the 
platelet glycoprotein (GP) VI (collagen) receptor, were 
higher in the TIC group compared with the TIC+ASP 
group suggesting that TIC is insufficient to completely 
supress collagen-mediated platelet activation. This 
effect was also observed in healthy volunteer stud-
ies,14,15,30 although only at high concentrations of the 
collagen agonist, which has less specificity for the GPVI 
receptor than CRP.31 The GPVI receptor is essential 
for normal haemostasis32 and mediates platelet activa-
tion through downstream signalling pathways that are 
dependent on TxA2 synthesis and thereby are highly 
sensitive to aspirin.33 We were unable to demonstrate 
a difference between the treatment groups in surface 
expression of the activation markers PAC 1 and an-
ti-CD62P after stimulation with CRP, possibly reflect-
ing limited sensitivity of this flow cytometry assay to 
differences in activation responses compared with the 
gold-standard light transmission aggregation.34
Our findings also provide potential mechanis-
tic explanations for differences in adverse events 
observed in recent randomized controlled trials 
of P2Y12 antagonist monotherapy versus DAPT. In 
particular, they suggest that the lower incidence 
of bleeding in the P2Y12 antagonist monotherapy 
groups in the TWILIGHT and SMART-CHOICE tri-
als17,19 may be attributable to partial preservation of 
platelet GPVI-mediated activation pathways in the 
monotherapy group, compared with more complete 
suppression from aspirin in the DAPT group. In the 
GLOBAL LEADERS study overall bleeding was sim-
ilar in the P2Y12 antagonist monotherapy and DAPT 
Figure 5. Platelet binding of the PAC 1 and anti-CD62P 
activation markers from blood sample 2.
A, baseline activation marker binding without agonist stimulation. 
B, the increase in activation marker binding after stimulation with 
thrombin receptor activation peptide 6 (TRAP-6) 5 μmol/L or with 
collagen related peptide (CRP) 1μg/mL. The data are expressed 
as the median (interquartile range) of the median fluorescent 
intensity of binding of PAC 1 or anti-CD62P.
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groups.18 However, in a posthoc analysis of the 
acute coronary syndrome cohort, increased bleed-
ing in the DAPT group compared with the P2Y12 
antagonist monotherapy group was observed be-
tween 1 and 12 months after treatment allocation 20, 
supporting the notion that across all patient groups 
avoidance of aspirin diminishes bleeding. It is also 
noteworthy that despite different bleeding rates in 
the treatment groups, thrombotic outcomes were 
not more frequent in the P2Y12 antagonist mono-
therapy groups.17–19 Several potential explanations 
for this apparent mismatch have been proposed.16,35 
However, our data raise the additional possibility 
that the similar anti-thrombotic effects of P2Y12 an-
tagonist monotherapy and DAPT could reflect their 
similar inhibitory effect on the platelet thrombin ac-
tivation pathway, which is an essential component 
of the stepwise models of pathogenesis of ath-
erothrombosis23,24 but may be partially redundant 
with collagen-mediated platelet activation in normal 
haemostasis.32,36 Considered alongside the clinical 
outcome data, our findings support comprehensive 
platelet inhibition with DAPT early after PCI when 
thrombotic risk is highest. They suggest further the 
potential for subsequent cessation of aspirin to di-
minish bleeding by reducing platelet inhibition and by 
specifically minimising gastrointestinal tract bleed-
ing for which aspirin is a contributory factor because 
of inhibition of gastroprotective prostanoids.13
Strengths and Limitations
A major strength of the TEMPLATE study was that it 
enabled pharmacodynamic assessment of TIC com-
pared to DAPT with TIC+ASP in a randomized set-
ting. Allocation bias was avoided through concealed 
allocation. Blood samples were analyzed in a single 
laboratory, thereby avoiding inter-laboratory variability. 
Laboratory personnel conducting the analyses were 
blinded to the group allocation. The broad selection of 
platelet activators confirmed that the platelet ADP and 
TxA2 pathways were strongly inhibited by the study 
drugs (aggregation responses with ADP and AA), but 
also enabled evaluation of platelet pathways important 
in pathological thrombosis (aggregation responses 
TRAP-6 and CRP).
The main imitations were that the study is small, 
and the participants were recruited from a single cen-
ter, thereby limiting the generalizability of the findings. 
The clinical teams were also not blinded to the treat-
ment allocation of the participants. There is a small 
possibility that platelet responses to the treatment 
drugs could have been different in the study cases en-
rolled at 12 months after PCI compared with patients 
enrolled earlier after PCI, as were evaluated in the 
TWILIGHT and GLOBAL LEADERS studies.16,18 The 
study necessarily evaluated platelet function ex vivo 
using tests that are insensitive to regulators of plate-
let activation released locally in the vasculature such 
as prostacyclin. Synthesis of this important negative 
regulator of platelet activation is inhibited by aspirin, 
thereby offsetting the main anti-thrombotic effect of 
aspirin that occurs through inhibition of platelet TxA2 
synthesis.37,38 This effect is unlikely to be detected in 
ex vivo platelet function tests thereby potentially lead-
ing to an overestimation of overall anti-thrombotic ef-
fect of aspirin. The study was insufficiently powered 
to test whether the differences between the treatment 
groups were consistent across all patient subgroups 
such as diabetes mellitus versus no diabetes mellitus 
or smokers versus non-smokers. Since these charac-
teristics influence baseline platelet reactivity, this is an 
attractive area of future investigation.
CONCLUSIONS
Monotherapy with the strong P2Y12 antagonist tica-
grelor results in less complete inhibition of collagen 
GPVI-mediated platelet activation when compared 
with DAPT with TIC+ASP. This finding may par-
tially contribute to the increased bleeding in pa-
tients receiving DAPT compared with potent P2Y12 
antagonists.
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SUPPLEMENTAL MATERIAL 
Table S1. Light transmission aggregation responses for the study patients 
subdivided according to treatment group. 
Agonist Blood 
sample 
TIC + ASP TIC  Model treatment effect 
Median MA (IQR) n Median MA (IQR) n Coefficient 95% CI p-value 
TRAP-6 
10 M 
1 81.5 (77.0, 91.0) 54 81.0 (75.0, 90.0) 53 - - - 
2 81.0 (78.0, 90.0) 47 86.0 (79.0, 93.5) 52 4.29 -0.87, 9.46 0.103 
3 86.0 (83.0, 96.0) 49 88.0 (83.0, 97.0) 50 - - - 
TRAP-6  
5 M 
1 73.5 (63.0, 84.0) 54 73.0 (67.0, 81.0) 53 - - - 
2 73.0 (68.0, 82.0) 47 81.0 (74.5, 87.0) 52 7.73* -0.13, 15.59 0.054 
3 84.0 (78.0, 91.0) 49 84.0 (79.0, 92.0) 50 - - - 
CRP  
1 g/mL 
1 85.0 (78.0, 92.0) 54 84.0 (78.5, 93.0) 52 - - - 
2 85.0 (80.0, 94.0) 47 91.5 (87.0, 100.5) 52 6.47 2.04, 10.90 0.004 
3 92.0 (86.0, 99.0) 49 92.5 (85.0, 97.0) 48 - - - 
CRP 
0.5g/mL 
1 77.0 (61.0, 85.0) 54 76.0 (64.0, 86.0) 53 - - - 
2 76.0 (65.0, 82.0) 47 89.0 (82.0, 95.0) 51 14.00* 7.63, 20.39 <0.001 
3 85.0 (80.0, 91.0) 49 86.0 (82.0, 96.0) 49 - - - 
U46619  
5 M 
1 78.0 (66.0, 86.0) 53 76.0 (69.0, 85.0) 53 - - - 
2 74.0 (66.0, 84.0) 47 74.5 (64.0, 81.5) 52 -1.41* -6.01, 3.18 0.547 
3 88.0 (85.0, 93.0) 48 88.5 (86.0, 93.0) 50 - - - 
U46619 
2.5 M 
1 49.0 (35.0, 64.0) 53 47.0 (33.0, 61.0) 53 - - - 
2 47.0 (35.0, 63.0) 47 44.5 (33.5, 67.0) 52 0.35* -7.73, 8.43 0.932 
3 85.0 (78.5, 91.0) 48 82.0 (77.0, 91.0) 50 - - - 
ADP  
10 M  
1 41.5 (32.0, 56.0) 54 43.0 (33.0, 56.0) 53 - - - 
2 34.0 (30.0, 41.0) 46 36.5 (29.0, 42.0) 52 1.15 -4.89, 7.19 0.709 
3 77.0 (71.0, 85.0) 49 75.0 (71.0, 83.0) 50 - - - 
AA 
1 mM 
1 6.5 (4.0, 9.0) 54 5.0 (3.0, 8.0) 53 - - - 
2 5.0 (3.0, 8.0) 47 75.0 (59.0, 83.0) 52 11.68 8.55, 15.95 <0.001 
3 7.0 (4.0, 10.0) 49 6.0 (4.0, 8.0) 50 - - - 
 
 
The data are expressed as the median (interquartile range) of the maximum 
aggregation responses at the stated agonist concentrations. TRAP-6- thrombin 
receptor activation peptide 6; CRP- collagen related peptide; U46619- thromboxane 

















Table S2. Platelet activation marker binding for the study patients subdivided 






TIC + ASP TIC 
Median MFI 
(IQR) 





1 PAC-1 117(60) 53 113 (69) 53 
1 CD62P 24 (21) 54 23 (17) 53 
2 PAC-1 122 (88) 48 112 (82) 53 
2 CD62P 25 (23) 48 22 (18) 52 
3 PAC-1 166 (117) 48 138 (99) 49 
3 CD62P 37 (28) 48 28 (23) 50 
TRAP-6 5 M 
1 PAC-1 1494 (1106) 52 1349 (1131) 53 
1 CD62P 3056 (2171) 52 3071 (1597) 53 
2 PAC-1 1286 (1501) 48 1206 (765) 53 
2 CD62P 3012 (3242) 48 2903 (2789) 53 
3 PAC-1 3934 (3434) 48 3847 (3588) 50 
3 CD62P 4511 (5370) 48 3811 (5344) 50 
CRP 1 g/mL 
1 PAC-1 2997 (444) 52 2812 (1304) 53 
1 CD62P 3498 (2731) 52 3378 (2256) 53 
2 PAC-1 3128 (2323) 48 3056 (1508) 50 
2 CD62P 3405 (5248) 48 3224 (2718) 50 
3 PAC-1 4342 (3300) 47 3729 (3398) 49 
3 CD62P 4614 (5682) 48 4205 (6174) 49 
 
The data are expressed as the median (interquartile range) of the median 
fluorescent intensity of binding of the PAC-1 or CD62P activation markers at without 
agonist stimulation and the increase in median fluorescent intensity after stimulation 










Table S3. Adverse events and serious adverse events for the entire study 
duration. 
 
TIC + ASP (N=49) TIC  (N=54) 

















Any event 115/38 69 1/1 2 143/45 82 6/2 4 
Bleeding * 37/27 49 0/0 0 20/16 29 0/0 0 
Eye 0/0 0 0/0 0 1/1 2 0/0 0 
Oral 1/1 2 0/0 0 3/3 5 0/0 0 
Epistaxis 4/4 7 0/0 0 0/0 0 0/0 0 
Subcutaneous or dermal 23/23 47 0/0 0 14/14 26 0/0 0 
Post procedural 1/1 2 0/0 0 0/0 0 0/0 0 
Wound 2/2 4 0/0 0 1/1 2 0/0 0 
TraumaTIC 2/2 4 0/0 0 1/1 2 0/0 0 
Other bleeding 4/3 5 0/0 0 0/0 0 0/0 0 
GI tract 19/9 16 0/0 0 42/22 40 0/0 0 
Abdominal pain 3/3 5 0/0 0 3/3 6 0/0 0 
Nausea 6/5 9 0/0 0 9/6 11 0/0 0 
Vomiting 3/3 5 0/0 0 6/4 7 0/0 0 
Diarrhoea 6/4 7 0/0 0 14/14 25 0/0 0 
Constipation 0/0 0 0/0 0 2/2 4 0/0 0 
Dyspepsia 1/1 2 0/0 0 8/7 13 0/0 0 
Liver 2/1 2 0/0 0 0/0 0 0/0 0 
Abnormal LFT 2/1 2 0/0 0 0/0 0 0/0 0 
Skin 4/3 5 0/0 0 10/8 15 1/1 2 
Skin reaction 4/3 5 0/0 0 10/8 15 1/1 2 
Neurology 8/6 11 0/0 0 9/8 15 0/0 0 
Confusion 1/1 2 0/0 0 0/0 0 0/0 0 
Dizziness 2/2 4 0/0 0 1/1 2 0/0 0 
Headache 3/3 5 0/0 0 4/4 7 0/0 0 
Paraesthesia 1/1 2 0/0 0 4/4 7 0/0 0 
Vertigo 1/1 2 0/0 0 0/0 0 0/0 0 
Kidney 3/2 4 0/0 0 4/4 7 1/1 2 
Water retention 2/2 4 0/0 0 2/2 4 0/0 0 
Poor renal function  1/1 2 0/0 0 2/2 4 1/1 2 
Respiratory 16/15 27 0/0 0 20/20 36 0/0 0 
Bronchospasm 1/1 2 0/0 0 2/2 4 0/0 0 
Dyspnoea 15/15 27 0/0 0 18/18 33 0/0 0 
Other 25/17 31 0/0 0 36/24 44 2/2 4 
Hypersensitivity 0/0 0 0/0 0 4/3 5 0/0 0 
Other events 25/17 31 0/0 0 32/24 44 2/2 4 
MACE  1/1 2 1/1 2 2/1 2 2/1 2 
Death 1/1 2 1/1 2 0/0 0 0/0 0 
MI 0/0 0 0/0 0 1/1 2 1/1 2 
Revascularisation 0/0 0 0/0 0 1/1 2 1/1 2 
 
*All bleeding events were mild and did not require additional clinical intervention 
(BARC type 1). 
 
Table S4. Adverse events and serious adverse events during allocation to TIC 
or TIC+ASP. 
 
TIC + ASP (N=49) TIC  (N=54) 

















Any event 90/37 67 1/1 2 98/39 71% 1/1 2 
Bleeding * 33/25 45 0/0 0 20/16 29 0/0 0 
Eye 0/0 0 0/0 0 1/1 2 0/0 0 
Oral 1/1 2 0/0 0 3/3 5 0/0 0 
Epistaxis 4/4 7 0/0 0 0/0 0 0/0 0 
Subcutaneous or dermal 23/23 47 0/0 0 14/14 26 0/0 0 
Post procedural 1/1 2 0/0 0 0/0 0 0/0 0 
Wound 2/2 4 0/0 0 1/1 2 0/0 0 
Traumatic 2/2 4 0/0 0 1/1 2 0/0 0 
Other bleeding 0/0 0 0/0 0 0/0 0 0/0 0 
GI tract 13/7 16 0/0 0 29/14 40 0/0 0 
Abdominal pain 3/3 5 0/0 0 3/3 6 0/0 0 
Nausea 4/4 8 0/0 0 8/5 9 0/0 0 
Vomiting 2/2 4 0/0 0 5/3 5 0/0 0 
Diarrhoea 3/3 6 0/0 0 9/9 16 0/0 0 
Constipation 0/0 0 0/0 0 2/2 4 0/0 0 
Dyspepsia 1/1 2 0/0 0 2/2 4 0/0 0 
Liver 1/1 2 0/0 0 0/0 0 0/0 0 
Abnormal LFT 1/1 2 0/0 0 0/0 0 0/0 0 
Skin 2/2 4 0/0 0 7/6 11 1/1 2 
Skin reaction 2/2 4 0/0 0 7/6 11 1/1 2 
Neurology 8/6 11 0/0 0 9/8 15 0/0 0 
Confusion 1/1 2 0/0 0 0/0 0 0/0 0 
Dizziness 2/2 4 0/0 0 1/1 2 0/0 0 
Headache 3/3 5 0/0 0 4/4 7 0/0 0 
Paraesthesia 1/1 2 0/0 0 4/4 7 0/0 0 
Vertigo 1/1 2 0/0 0 0/0 0 0/0 0 
Kidney 2/2 4 0/0 0 2/2 4 0/0 0 
Water retention 2/2 4 0/0 0 2/2 4 0/0 0 
Poor renal function  0/0 0 0/0 0 0/0 0 0/0 0 
Respiratory 15/15 27 0/0 0 18/18 33 0/0 0 
Bronchospasm 0/0 0 0/0 0 0/0 0 0/0 0 
Dyspnoea 15/15 27 0/0 0 18/18 33 0/0 0 
Other 15/15 27 0/0 0 13/12 22 1/1 2 
Hypersensitivity 0/0 0 0/0 0 2/2 4 0/0 0 
Other events 15/15 27 0/0 0 11/11 20 1/1 2 
MACE  1/1 2 1/1 2 0/0 0/0 0/0 2 
Death 1/1 2 1/1 2 0/0 0 0/0 0 
MI 0/0 0 0/0 0 0/0 0 0/0 0 
Revascularisation 0/0 0 0/0 0 0/0 0 0/0 0 
 
*All bleeding events were mild and did not require additional clinical intervention 
(BARC type 1). 
 
Figure S1. Platelet binding of the PAC 1 and anti-CD62P activation markers 






































At this time point all patients all patients were receiving ASP plus a P2Y12 blocker (ticagrelor 
44%; clopidogrel 35%; or prasugrel 21%). A. baseline activation marker binding without 
agonist stimulation, and, B. the increase in activation marker binding after stimulation with 
thrombin receptor activation peptide 6 (TRAP-6) 5 M or with collagen related peptide (CRP) 
1g/mL The data are expressed as the median (interquartile range) of the median 

































































Figure S2. Platelet binding of the PAC 1 and anti-CD62P activation markers 





































At this time point all patients were receiving monotherapy with ASP. A. baseline 
activation marker binding without agonist stimulation, and, B. the increase in 
activation marker binding after stimulation with thrombin receptor activation peptide 6 
(TRAP-6) 5 M or with collagen related peptide (CRP) 1g/mL. The data are 
expressed as the median (interquartile range) of the median fluorescent intensity of 
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